CONSENTIS is geared to alleviate the challenges posed by personal data sharing towards the implementation of EU regulations and strategic initiatives like eIDAS, EU Data Spaces and GDPR. It introduces a novel framework which offers Self-Sovereign Identity and user-centric consent management solutions that enables users to (a) have full control over their personal data collection and usage and (b) provide informed consent through user-friendly interfaces and notifications. The proposed framework is agnostic to existing services and formats and guarantees high levels of protection avoiding potential legal uncertainty, through a continuous assessment mechanism for security, risk and legal aspects. CONSENTIS is an industry-oriented project, with SMEs and large companies covering more than 80% of the consortium and is built on a collaboration of 12 organisations from 9 EU member states and associated countries. The Consortium includes: 2 academic institutions, 8 SMEs and 2 large industry partners that bear strong interest and relevance to the project objectives and are highly committed in the delivery of scientific excellence and innovation in the fields of identity management and SSI, consent management, blockchain and smart contracts, user interfaces/user experience, cybersecurity and PETs, business and market impact and EU laws, policies and regulations for human rights and technology.

The latest cancer statistics highlight encouraging advances in decreasing cancer-related mortality. However, given that one in two people will be diagnosed with cancer in their lifetime, and due to the growing and ageing population, the absolute number of people living with cancer is set to keep increasing substantially in the near future. The main objective of ASCAPE is to take advantage of the recent ICT advances in Big Data, Artificial Intelligence and Machine Learning to support cancer patients’ quality of life and health status. To achieve its objective, ASCAPE will create an open AI infrastructure that will enable health stakeholders (hospitals, research institutions, companies, etc.) to deploy and execute its AI algorithms locally on their private data. Any new knowledge produced by this process will be sent back to the open AI infrastructure. This way the knowledge will be shared among everyone while the medical data will still remain private. The services to be designed, piloted and deployed inside this project will include intelligent interventions for physiological and psychological support, improved patient and family counselling and guidance, early diagnosis and forecasts of ill-health, identification of disease trajectories and relapse, improved health literacy etc. ASCAPE will focus the training of the AI in two types of cancer, breast and prostate. This way, it will achieve sufficient coverage across genders as well as age groups, hence facilitating its ongoing improvements and applicability towards any type of cancer in the future. The ASCAPE project will be developed in 36 months by a competitive consortium of 15 partners from 7 countries, which corresponds to a well-balanced structure, involving big companies, SMEs, research centres and universities. Despite the great diversity of entities within the proposal, ASCAPE partners bring state-of-the-art complementary skills ensuring the ability of the consortium to develop the proposed solutions.